Conference Coverage: EHA 2022 – Focus on Lymphoma

Lymphoma-specific discussions on the latest research updates, therapeutic advances, and their application in clinical decision-making

June 16, 2022


Brad S. Kahl, MD

Washington University School of Medicine, St Louis, MO, USA

Faculty Members

Matthew Lunning, DO, FACP
University of Nebraska Medical Center, Omaha, NE, USA

Paolo Caimi, MD
Case Comprehensive Cancer Center, Cleveland, OH, USA

Stefan Barta, MD, MS, MRCPCUK
Penn Medicine, Philadelphia, PA, USA

John Gribben, MD, DSc, FRCP, FRCPath
Cancer Research UK Barts Centre, London, United Kingdom

Pier Luigi Zinzani, MD, PhD
University of Bologna Institute of Hematology and Medical Oncology, Bologna, Italy

Olivier Tournilhac, MD, PhD
Clermont Auvergne University, Clermont-Ferrand, France

Georg Hess, MD
Johannes Gutenberg University, Mainz, Germany

Sample Report

Start discovering the insights

View Report


  • Advances in DLBCL/Aggressive B-Cell Lymphoma
  • Advances in CAR T
  • Advances in FL
  • Advances in MCL and MZL
  • Evolving Use of BTK Inhibitors in CLL
  • Role of Fixed-Duration and MRD-Guided Strategies in CLL

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.